Amgen Just Survived Biotech's Most Notorious Graveyard

Then there's the placebo problem. Lupus patients in clinical trials tend to improve on placebo at surprisingly high rates, partly because of the background immunosuppressants they're already taking. That high placebo response can erase the statistical gap between drug and sugar pill, even when the drug is actually doing something.

The approved drug list tells the story. For decades, lupus patients had almost nothing beyond steroids and generic immunosuppressants. GSK's Benlysta (belimumab) broke through as the first new lupus drug in over 50 years, but it took a brutal development path to get there. AstraZeneca's anifrolumab eventually made it too, though an early pivotal trial missed its primary endpoint before later studies pulled the program back from the brink.

Meanwhile, the failures kept piling up. Just this month, Immunovant's FcRn antibody missed its primary endpoint in cutaneous lupus. Alumis struck out on both primary and secondary endpoints in a phase 2b systemic lupus trial. The graveyard is still accepting new residents.

The Catch (Because There's Always a Catch)

Before anyone starts printing "Amgen cured lupus" t-shirts, some important context: this was a discoid lupus study, not systemic lupus. Discoid lupus affects the skin; systemic lupus can ravage internal organs. They're related but different beasts.

And here's the part that should temper the celebrations: Amgen's earlier study of daxdilimab in systemic lupus erythematosus didn't deliver the efficacy the company wanted. That's a significant caveat. Winning in discoid lupus is genuinely impressive, but the bigger commercial prize (and the harder scientific challenge) is SLE, where the drug has already stumbled once.

Amgen is now weighing whether to advance directly to phase 3, and whether that next trial should stick with discoid lupus specifically or expand to a broader cutaneous lupus population. That decision will say a lot about how confident the company really is in the data.

Amgen's Bigger Autoimmune Play

This lupus readout doesn't exist in a vacuum. Amgen has been quietly assembling one of the more ambitious autoimmune pipelines in pharma, and the lupus data is one piece of a much larger puzzle.

The company's anchor is UPLIZNA (inebilizumab), already approved in AQP4-antibody-positive neuromyelitis optica spectrum disorder, IgG4-related disease, and generalized myasthenia gravis, with expansion studies planned in autoimmune hepatitis and CIDP. In Sjögren's disease, Amgen has two phase 3 trials running for dazodalibep; one trial (OASIZ 301) has already reported positive topline results, while the other (OASIZ 303) has results expected in Q4 2026. And the company is testing blinatumomab (yes, the leukemia drug) in both SLE and refractory rheumatoid arthritis.

The common thread? B-cell mediated autoimmunity. Amgen is betting that targeting B cells and their accomplices across multiple diseases can create a durable franchise, not just a one-drug wonder. It's the portfolio approach: if lupus doesn't pan out at the systemic level, Sjögren's or autoimmune hepatitis might carry the weight.

What Wall Street Thinks

Analysts are treating this as a "nice to have" rather than a "must have" for the Amgen thesis right now. The lupus data is credible and positive, but investors are more focused on the Sjögren's phase 3 results, which represent a closer, larger commercial opportunity.

That's not a knock on the lupus data; it's just math. A 72-patient phase 2 in discoid lupus doesn't move the needle for a company with Amgen's market cap. But it does something arguably more important: it validates the mechanism. If ILT7 depletion works in discoid lupus, it strengthens the scientific rationale for testing the approach in broader lupus populations and potentially other interferon-driven diseases.

The Bottom Line

Lupus remains one of the hardest problems in medicine. Roughly 3.4 million people worldwide live with SLE, many of them relying on decades-old treatments that come with brutal side effects. The market needs new options desperately.

Amgen just proved that its approach can work in at least one form of the disease. That's not a cure, and it's not a guarantee that phase 3 will succeed. But in a therapeutic area where most companies leave empty-handed, walking out with clean, positive data from both dose arms is worth paying attention to.

The real test comes next: can Amgen take this signal and turn it into something that helps the patients who need it most? Lupus has humbled bigger bets than this one. But for now, Amgen is one of the few companies that can say it went into the graveyard and came back out.

The Obesity Drug That Worked Better at a Lower Dose

Zealand Pharma's obesity drug petrelintide posted 9.8% weight loss in Phase 2, but with a catch: the middle dose outperformed the highest one. The inverted dose-response curve complicates Phase 3 planning and raises fascinating questions about the limits of amylin biology.